Released on = July 6, 2007, 10:44 am

Press Release Author = Aesis Research Group

Industry = Biotech

Press Release Summary = The Aesis Group is very pleased to announce the debut of its
blog, the Life Sciences Business and Investment Daily which can be found at
http://blog.aesisgroup.com. This blog highlights important trends and developments
in the biopharma, medical technology and healthcare sectors particularly as they
relate to their business and investment implications.

Press Release Body = Chicago - July 6, 2007 - The Aesis Group is very pleased to
announce the debut of its blog, the Life Sciences Business and Investment Daily
which can be found at http://blog.aesisgroup.com. This blog highlights important
trends and developments in the biopharma, medical technology and healthcare sectors
particularly as they relate to their business and investment implications.

A broad range of topics is but some important themes include:

* convergent medical technologies (a.k.a. combination medical products),
* personalized medicine,
* clinical trials,
* patient safety,
* new business models for the life sciences,
* innovation and intellectual property, and
* emerging medical technologies in general.

Future topics will also highlight developments in stem cell (regenerative medicine)
technologies and medical nanotechnology. Though the Life Sciences industry is truly
global, the blog will also consider developments specific to the Midwest and the
Chicago/Illinois area. The Life Sciences Business & Investment Daily is also
positioned as a leading information portal on convergent medical technologies as the
site already features a dozen entries on that subject alone. The meta-themes of the
blog will be that of independence and integration - two features that are
particularly critical to creating deals and making them work.

Dr. Ogan Gurel is the principal blogger on the site. He is chairman of the Aesis
Group, a healthcare and life sciences consultancy. Dr. Gurel is also a regular
columnist in biopharma/medtech for several online venues including
Midwestbusiness.com, a juror for the 2007/2008 Medical Design Excellence Awards and
an Adjunct Associate Professor of Bioengineering at the University of Illinois at
Chicago.

Gurel was previously CEO of Duravest - a publicly traded Chicago company that
develops next-generation convergent medical technologies and prior to that Vice
President and Medical Director at Sg2 - a leading healthcare intelligence firm and
consultancy. Dr. Gurel's scientific work has been published in the peer-reviewed
literature and his business commentaries have been published worldwide including the
Wall Street Journal. He has conducted research in computer science winning 3rd
place in the national Westinghouse (now Intel) Science Talent Search and has taught
a number of subjects - cellular and molecular biology, neuroanatomy, bioinformatics
and mathematical modeling - at several universities including Columbia, Roosevelt
and Harvard Universities.


Background on the Aesis Research Group, LLC

The Aesis Group (www.aesisgroup.com) is a life sciences and healthcare consultancy
which provides a number of services including, strategic advisory, clinical trials
advisory, market forecasting, technology investment, portfolio optimization, deal
sourcing and investment due diligence services. Clients have included startups,
hospitals, health systems, GPOs, private equity firms, venture capital funds and
hedge funds in sectors such as healthcare IT, urology, cardiology, orthopedics,
neurosciences, teleradiology, surgery and others.

For more information contact the Aesis Group at info@aesisgroup.com



Web Site = http://blog.aesisgroup.com/

Contact Details = PO Box 578025
Chicago, IL 60657-8025
T: (312) 246-5160
F: (773) 409-5897
info@aesisgroup.com